ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SAR Sareum Holdings Plc

11.00
-3.50 (-24.14%)
Last Updated: 13:25:38
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Sareum Holdings Plc LSE:SAR London Ordinary Share GB00BMC3RJ87 ORD GBP 0.0125
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.50 -24.14% 11.00 10.50 11.50 12.00 10.50 12.00 6,647,665 13:25:38
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -3.19M -0.0469 -2.35 7.49M

Sareum Holdings PLC Phase 1a clinical trial for SDC-1801 (8615Z)

18/05/2023 7:00am

UK Regulatory


Sareum (LSE:SAR)
Historical Stock Chart


From Mar 2023 to Mar 2024

Click Here for more Sareum Charts.

TIDMSAR

RNS Number : 8615Z

Sareum Holdings PLC

18 May 2023

Sareum Holdings PLC

("Sareum" or the "Company")

Sareum announces the commencement of a Phase 1a clinical trial for SDC-1801

Cambridge, UK , 18 May 2023 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces the initiation of a Phase 1a clinical trial for its lead product SDC-1801. The trial has started with patient recruitment in progress at specialist clinical units located in Victoria, Australia.

SDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune condition affecting the skin.

This follows the recent approval of the Company's application under the Clinical Trial Notification (CTN) scheme by the Human Research Ethics Committee (HREC). Australia's medicines regulator, the Therapeutic Goods Administration (TGA), has also acknowledged the application, allowing for the Phase 1a trial to proceed.

The initial Phase 1a trial is designed to investigate the safety and pharmacokinetics of an oral formulation of SDC-1801 in healthy subjects (trial ID ACTRN12623000416695p ). Provided satisfactory safety data are obtained from this initial study, a Phase 1b clinical study is expected to commence in psoriasis patients in 2024 .

-Ends-

For further information, please contact:

 
 Sareum Holdings plc 
  Tim Mitchell, CEO                                 01223 497700 
  Lauren Williams, Head of Investor Relations       ir@sareum.co.uk 
 Strand Hanson Limited (Nominated Adviser) 
  James Dance / James Bellman                       020 7409 3494 
 Peel Hunt LLP (Joint Corporate Broker) 
  James Steel / Oliver Duckworth                    020 7418 8900 
 Hybridan LLP (Joint Corporate Broker) 
  Claire Noyce                                      020 3764 2341 
 Consilium Strategic Communications (Financial 
  PR) 
  Jessica Hodgson / Davide Salvi / Stella 
  Lempidaki                                         020 3709 5700 
 

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCGUGDURUBDGXI

(END) Dow Jones Newswires

May 18, 2023 02:00 ET (06:00 GMT)

1 Year Sareum Chart

1 Year Sareum Chart

1 Month Sareum Chart

1 Month Sareum Chart

Your Recent History

Delayed Upgrade Clock